KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Consolidated Net Income: 2014-2024

Historic Consolidated Net Income for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Dec 2024 value amounting to $5.7 million.

  • Aurinia Pharmaceuticals' Consolidated Net Income rose 120.53% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 443.39%. This contributed to the annual value of $5.7 million for FY2024, which is 107.36% up from last year.
  • As of FY2024, Aurinia Pharmaceuticals' Consolidated Net Income stood at $5.7 million, which was up 107.36% from -$78.1 million recorded in FY2023.
  • Aurinia Pharmaceuticals' 5-year Consolidated Net Income high stood at $5.7 million for FY2024, and its period low was -$181.0 million during FY2021.
  • In the last 3 years, Aurinia Pharmaceuticals' Consolidated Net Income had a median value of -$78.1 million in 2023 and averaged -$60.2 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first slumped by 76.24% in 2021, then spiked by 107.36% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Consolidated Net Income (Yearly) stood at -$102.7 million in 2020, then tumbled by 76.24% to -$181.0 million in 2021, then surged by 40.22% to -$108.2 million in 2022, then increased by 27.83% to -$78.1 million in 2023, then surged by 107.36% to $5.7 million in 2024.